Literature DB >> 8886992

The molecular basis of natural killer (NK) cell recognition and function.

L Moretta1, M C Mingari, D Pende, C Bottino, R Biassoni, A Moretta.   

Abstract

Natural Killer cells are likely to play an important role in the host defenses because they kill virally infected or tumor cells but spare normal self-cells. The molecular mechanism that explains why NK cells do not kill indiscriminately has recently been elucidated. It is due to several specialized receptors that recognize major histocompatibility complex (MHC) class I molecules expressed on normal cells. The lack of expression of one or more HLA class I alleles leads to NK-mediated target cell lysis. Different types of receptors specific for groups of HLA-C, HLA-B, and, very recently, HLA-A alleles have been identified. While in most instances, they function as inhibitory receptors, an activatory form of the HLA-C-specific receptors has been identified in some donors. Molecular cloning of HLA-C-, HLA-B- or HLA-A-specific receptors has revealed new members of the immunoglobulin superfamily with two or three Ig-like domains, respectively, in their extracellular portion. While the inhibitory form is characterized by a long cytoplasmic tail associated with a non-polar transmembrane portion, the activatory one has a short tail associated with a Lys-containing transmembrane portion. Thus, these human NK receptors are different from the murine Ly49, that is a type II transmembrane protein characterized by a C-type lectin domain. A subset of activated T lymphocytes expresses NK-type class I-specific receptors. These receptors exert an inhibiting activity on T cell receptor-mediated functions and may provide an important mechanism of downregulation of T cell responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886992     DOI: 10.1007/bf01541388

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  66 in total

Review 1.  Candidate natural killer cell receptors.

Authors:  E Hofer; M Düchler; S A Fuad; J P Houchins; T Yabe; F H Bach
Journal:  Immunol Today       Date:  1992-11

2.  Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice.

Authors:  M Bix; N S Liao; M Zijlstra; J Loring; R Jaenisch; D Raulet
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

3.  Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production.

Authors:  M C Mingari; C Vitale; A Cambiaggi; F Schiavetti; G Melioli; S Ferrini; A Poggi
Journal:  Int Immunol       Date:  1995-04       Impact factor: 4.823

4.  NK susceptibility varies inversely with target cell class I HLA antigen expression.

Authors:  W J Storkus; D N Howell; R D Salter; J R Dawson; P Cresswell
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

Review 5.  Receptors for HLA class I molecules in human NK cells.

Authors:  C Bottino; M Vitale; D Pende; R Biassoni; A Moretta
Journal:  Semin Immunol       Date:  1995-04       Impact factor: 11.130

6.  T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function.

Authors:  S Ferrini; A Cambiaggi; R Meazza; S Sforzini; S Marciano; M C Mingari; L Moretta
Journal:  Eur J Immunol       Date:  1994-10       Impact factor: 5.532

7.  A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function.

Authors:  A Moretta; G Tambussi; C Bottino; G Tripodi; A Merli; E Ciccone; G Pantaleo; L Moretta
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

8.  Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles.

Authors:  A Moretta; M Vitale; S Sivori; C Bottino; L Morelli; R Augugliaro; M Barbaresi; D Pende; E Ciccone; M Lopez-Botet; L Moretta
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

9.  Human natural killer (NK) alloreactivity and its association with the major histocompatibility complex: ancestral haplotypes encode particular NK-defined haplotypes.

Authors:  F T Christiansen; C S Witt; E Ciccone; D Townend; D Pende; D Viale; L J Abraham; R L Dawkins; L Moretta
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

10.  Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells.

Authors:  A Moretta; S Sivori; M Vitale; D Pende; L Morelli; R Augugliaro; C Bottino; L Moretta
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more
  5 in total

1.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

2.  Alterations of natural killer cell and T-lymphocyte counts in adults infected with human immunodeficiency virus through blood and plasma sold in the past in China and in whom infection has progressed slowly over a long period.

Authors:  Yongjun Jiang; Hong Shang; Zining Zhang; Yingying Diao; Di Dai; Wenqing Geng; Min Zhang; Xiaoxu Han; Yanan Wang; Jing Liu
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 3.  Immunological basis of early clearance of Mycobacterium tuberculosis infection: the role of natural killer cells.

Authors:  F Abebe
Journal:  Clin Exp Immunol       Date:  2021-01-05       Impact factor: 5.732

Review 4.  Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28.

Authors:  F R Mariotti; L Quatrini; E Munari; P Vacca; N Tumino; G Pietra; M C Mingari; L Moretta
Journal:  Br J Pharmacol       Date:  2020-05-18       Impact factor: 8.739

Review 5.  NK Cell-Based Immune Checkpoint Inhibition.

Authors:  Muhammad Khan; Sumbal Arooj; Hua Wang
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.